首页 > 市场调查报告书 > 製药

精神疾病

市场调查报告书

商品编码

1629601

迷幻药市场：依药物类型、用途、通路、给药途径及地区划分

Psychedelic Drugs Market, By Drug Type, By Application, By Distribution Channel, By Route of administration, By Geography

出版日期: 2024年11月26日 | 出版商:

Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024 年全球迷幻药市场规模估计为 34.1 亿美元，预计到 2031 年将达到 83.2 亿美元，2024 年至 2031 年的复合年增长率为 13.6%。

报告范围		报告详细信息
基准年	2023	2024 年的市场规模	34.1亿美元
效能资料	2019 年至 2023 年	预测期	2024 年至 2031 年
预测期间 2024 年至 2031 年复合年增长率：	13.60％	2031 年价值预测	83.2亿美元

图。

近年来，随着迷幻药辅助心理治疗在精神疾病治疗中的接受度不断提高，全球迷幻药市场经历了显着增长。迷幻药，例如麦角酸二乙酰胺 (LSD)、裸盖菇素、3,4-亚甲基安非他命(MDMA)、氯胺酮和分离性药物，用于改变使用者的感知、思想和意识层级。忧郁症和其他精神疾病的盛行率不断上升，以及评估迷幻药治疗各种精神疾病疗效的临床研究数量不断增加，是推动市场成长的主要因素。此外，北美和欧洲多个政府采取的有利监管改革也对迷幻药在治疗抗治疗性忧郁症等疾病方面的应用产生了积极影响。

市场动态：

全球迷幻药市场的成长主要受以下因素推动：精神疾病盛行率不断上升、迷幻药相关的药物开发和临床研究不断进行、以及医生和患者对迷幻药辅助心理治疗的接受度不断提高。世界卫生组织估计，全球整体有超过2.64亿人患有忧郁症。迷幻药，例如裸盖菇素、LSD 和 MDMA，已显示出治疗重度忧郁症和其他精神疾病的潜力。越来越多的临床研究评估这些药物对抗治疗性忧郁症（TRD）和创伤后压力症候群（PTSD）等疾病的治疗效果，从而推动市场成长。此外，一些新兴经济体的法律规范允许迷幻药进一步商业化。然而，有关这些药物的临床和商业性使用的严格规定给市场带来了潜在的挑战。此外，娱乐用途合法化的风险可能会抑制迷幻药的治疗应用。另一方面，透过加强研究和创新开拓实证治疗模式为该市场的相关人员提供了机会。

本研究的主要特点

本报告对全球精神药物市场进行了详细分析，并提供了预测期（2024-2031 年）的市场规模（十亿美元）和年复合成长率（CAGR%），假设基准年为 2023 年。

它还强调了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。

它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。

它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，概述了全球迷幻药市场的主要企业。

研究中介绍的主要企业包括 MindMed、Compass Pathways、Cybin、Atai Life Sciences、Field Trip Health、Havn Life Sciences、Revive Therapeutics、NeonMind Biosciences、Numinus Wellness、PharmaTher Holdings、Jazz Pharmaceuticals、Seelos Therapeutics、NRx Pharmauticals、Psychednesss、Psychednessed。

本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。

全球迷幻药市场报告涵盖该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员可以透过用于分析全球迷幻药市场的各种策略矩阵来简化决策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	US$ 3.41 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	13.60%	2031 Value Projection:	US$ 8.32 Bn

The global psychedelic drugs market has witnessed significant growth in the past few years due to the increasing acceptance of psychedelic-assisted psychotherapy for the treatment of mental health conditions. Psychedelic drugs such as lysergic acid diethylamide (LSD), psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), ketamine, and dissociative drugs are used to alter users' perceptions, thoughts, and consciousness levels. Increasing prevalence of depression and other mental disorders as well as growing number of clinical research to evaluate the efficacy of psychedelic drugs for treatment of various mental health disorders is primarily driving the market growth. Moreover, favorable regulatory reforms by several governments across North America and Europe have positively impacted the adoption of psychedelic therapeutics for treatment of conditions such as treatment-resistant depression.

Market Dynamic:

The global psychedelic drugs market growth is primarily driven by factors such the increasing prevalence of mental disorders, ongoing drug development and clinical research related to psychedelic drugs, and growing acceptance of psychedelic-assisted psychotherapy among physicians and patients. According to the WHO estimates, over 264 million people suffer from depression globally. Psychedelic drugs such as psilocybin, LSD, and MDMA have shown potential for the treatment of major depressive disorder as well as other mental health conditions. The growing number of clinical studies to evaluate the therapeutic effects of these drugs for conditions like treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD) is fostering the market growth. Additionally, supportive regulatory framework in several developed economies is enabling the commercialization of psychedelic medicines. However, strict regulations regarding the clinical and commercial use of these drugs pose potential challenges for the market. Moreover, risk of legalized recreational use can restrain the therapeutic adoption of psychedelic drugs. Meanwhile, the development of evidence-based treatment paradigms by facilitating research and innovation represents an opportunity for stakeholders in this market.

Key features of the study:

This report provides an in-depth analysis of the global psychedelic drugs market and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global psychedelic drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include MindMed, Compass Pathways, Cybin Inc., Atai Life Sciences, Field Trip Health Ltd., Havn Life Sciences, Revive Therapeutics, NeonMind Biosciences, Numinus Wellness, PharmaTher Holdings Ltd., Jazz Pharmaceuticals, Seelos Therapeutics, NRx Pharmaceuticals Inc., Psyched Wellness Ltd., and Silo Wellness,

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global psychedelic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global psychedelic drugs market.

Market Segmentation

By Drug Type Insights (Revenue, USD Bn, 2019 - 2031)
- Gamma Hydroxybutyric Acid (GHB)
- Ketamine
- Psilocybin
- Lysergic Acid Diethylamide (LSD)
- 3,4-Methylenedioxymethamphetamine (MDMA)
- Other Drug Types (Mescaline, etc.)
By Application Insights (Revenue, USD Bn, 2019 - 2031)
- Mental Health Disorders
- Depression
- Anxiety
- PTSD (Post-Traumatic Stress Disorder)
- Substance Use Disorders
- Neurological Disorders
- Alzheimer's Disease
- Parkinson's Disease
- Pain Management:
- Chronic Pain
- Migraines
- Other Applications:
- Obsessive-Compulsive Disorder (OCD)
- Others (Opiate Addiction, etc.)
By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Intravenous
- Inhalation
- Intranasal
- Others (Rectal)
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- MindMed
- Compass Pathways
- Cybin Inc.
- Atai Life Sciences
- Field Trip Health Ltd.
- Havn Life Sciences
- Revive Therapeutics
- NeonMind Biosciences
- Numinus Wellness
- PharmaTher Holdings Ltd.
- Jazz Pharmaceuticals
- Seelos Therapeutics
- NRx Pharmaceuticals Inc.
- Psyched Wellness Ltd.
- Silo Wellness

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Psychedelic Drugs Market, By Drug Type
- Global Psychedelic Drugs Market, By Application
- Global Psychedelic Drugs Market, By Distribution Channel
- Global Psychedelic Drugs Market, By Route of Administration
- Global Psychedelic Drugs Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Psychedelic Drugs Market, By Drug Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Gamma Hydroxybutyric Acid (GHB)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Ketamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Psilocybin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Lysergic Acid Diethylamide (LSD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
3,4-Methylenedioxymethamphetamine (MDMA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Other Drug Types (Mescaline, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Psychedelic Drugs Market, By Application, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Mental Health Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Depression
Anxiety
PTSD (Post-Traumatic Stress Disorder)
Substance Use Disorders
Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Alzheimer's Disease
Parkinson's Disease
Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Chronic Pain
Migraines
Other Applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Obsessive-Compulsive Disorder (OCD)
Others (Opiate Addiction, etc.)

6. Global Psychedelic Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Psychedelic Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others (Rectal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Psychedelic Drugs Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

MindMed
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Compass Pathways
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cybin Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Atai Life Sciences
Field Trip Health Ltd.
Havn Life Sciences
Revive Therapeutics
NeonMind Biosciences
Numinus Wellness
PharmaTher Holdings Ltd.
Jazz Pharmaceuticals
Seelos Therapeutics
NRx Pharmaceuticals Inc.
Psyched Wellness Ltd.
Silo Wellness

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

迷幻药市场：依药物类型、用途、通路、给药途径及地区划分